Reports Q3 revenue $133.0M, consensus $130.5M. “Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. “Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance. We also made important progress across the pipeline, including completing enrollment in the VISTAS PSC study, maintaining momentum in VANTAGE and EXPAND, and initiating our Phase 2 study in Fragile X Syndrome.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- MIRM Upcoming Earnings Report: What to Expect?
- Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
- Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
- Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact